

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION**

Reference is made to the announcement made by Lee's Pharmaceutical Holdings Limited (the "**Company**") on 18 November 2019 for connected transaction (the "**Transaction Announcement**"). Terms defined in this announcement shall have the same meanings as those defined in the Transaction Announcement unless the context otherwise requires.

The Company hereby provides additional information as follows:-

#### **FURTHER INFORMATION ON LEE'S INTERNATIONAL**

As stated in the Transaction Announcement, Lee's International is a wholly owned subsidiary of the Company and its principal business activity is investment holding.

#### **FURTHER INFORMATION ON PPI**

As stated in the Transaction Announcement, PPI was incorporated in the British Virgin Islands on 6 August 2009 and is currently carrying on the business of, inter alia, producing, developing and sale of Zingo and the platform together with the accompanying powder intra-dermal injection system, and other medical devices such as the developing of continuous glucose monitoring system. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, the shareholding structure of PPI is as follows:-

<b>Shareholders of PPI</b>	<b>Shareholding</b>	<b>Remark</b>
Lee's International	33.92%	Lee's International is a wholly owned subsidiary of the Company.
DF Pharma Investment Limited	20.12%	DF Pharma Investment Limited is wholly owned by a fund (the "Fund") managed by its general partner, namely GL Partners Capital Management Limited, and the Fund is owned as to 98% by Assicurazioni Generali, S.p.A., a company with its shares listed in Milan Stock Exchange.
Minter Chemical Limited	11.47%	Minter Chemical Limited is wholly owned by Mr. Huang Wei, who is, to the best of the Directors' knowledge, information and belief having made all reasonable enquiry, a third party independent of the Company and its connected persons.
Swift Power Investments Limited	8.15%	Swift Power Investments Limited is wholly owned by Dr. Li Xiaoyi, who is an executive director of the Company.
Dr. Li Xiaoyi	0.69%	Dr. Li Xiaoyi is an executive director of the Company.
Other investors	25.65%	The shareholdings of each of the other investors is less than 10%.
Total	100.00%	

All other information set out in the Transaction Announcement remains unchanged.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 20 November 2019

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Mr. Simon Miles Ball is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.*